Sandoz's distribution of Delysid

Sandoz’s distribution of Delysid made LSD available to a widening circle of researchers and helped create the practical conditions for the first wave of psychedelic investigation. The drug did not travel alone: in Al Hubbard’s hands, ampules moved between research centers together with clinical expertise and a distinctive approach to treatment. Its circulation connected scattered experiments, helped establish new research hubs, and carried LSD beyond the clinic into disputes about creativity, spirituality, and the limits of scientific medicine.

From compound to research resource

The book identifies the distribution of LSD-25 under the name Delysid as a starting point for the network of research hubs that developed around the drug. The significance of that circulation lies not only in the compound itself but in its availability to people who could administer it, study its effects, and compare approaches. The account’s index returns to the distribution at several points in its history, reflecting how the drug’s movement through research settings became part of the larger story of psychedelic therapy.

The available evidence does not describe the terms or logistics of Sandoz’s distribution in detail. It does, however, show what happened as LSD entered researchers’ hands: ampules of Sandoz LSD became part of the practical equipment through which investigators and therapists pursued their work. Delysid therefore figures as an enabling resource, not as a therapeutic method in its own right. What researchers did with the drug depended on the settings they created, the people who guided sessions, and the questions they brought to them.

Hubbard as a distributor and connector

By the late 1950s, Al Hubbard had become a traveling intermediary in North American psychedelic research. He moved among centers, including Weyburn, Manhattan, Los Angeles, and Vancouver, bringing both Sandoz LSD and therapeutic advice. In Weyburn he assisted Humphry Osmond and Abram Hoffer in their work with people with alcohol dependence; in Manhattan he met R. Gordon Wasson; and in Los Angeles he worked with Betty Eisner, Sidney Cohen, and Oscar Janiger. The itinerary makes distribution visible as a human network: a supply of ampules could connect researchers who were separated by geography and institutional affiliation.

Hubbard also carried the work into treatment settings. At Hollywood Hospital in Vancouver, he persuaded the institution to dedicate a wing to treating alcoholics with LSD, and he established two other alcoholism-treatment facilities in Canada. He sometimes flew his plane to Los Angeles to bring celebrities discreetly to Vancouver for treatment, earning the nickname Captain Trips. The book presents these efforts as more than the delivery of a substance: Hubbard circulated techniques as well as LSD, and his movement between sites helped transfer clinical experience from one group to another.

The distribution network also created tensions over who should benefit from treatment. Hubbard regarded psychedelic therapy as philanthropic and opposed making a profit from LSD, while some institutions charged patients more than five hundred dollars for a session. That disagreement exposes a consequence of the drug’s expanding availability: once LSD could support an organized treatment service, questions of access and payment became inseparable from questions about its medical use. Hubbard’s own fortune was depleted as he advanced the work, a personal cost that contrasts with the fees charged by institutions using the method.

From clinical sessions to new research sites

Hubbard’s supply and guidance reached Menlo Park, where Myron Stolaroff and colleagues at Ampex began meeting to discuss LSD and the potential of healthy people to realize their capacities. Hubbard came to guide their psychedelic journeys and train them to guide others. Stolaroff later tried, with Hubbard’s help, to reshape Ampex into what he called a psychedelic corporation, including weekly workshops at company headquarters and LSD sessions for executives at a site in the Sierra. The project faltered after the company’s general manager objected to religious images Hubbard had placed in his office, showing how the treatment’s spiritual elements could complicate its entry into a workplace.

In 1961, Stolaroff left Ampex to devote himself full-time to psychedelic research. With Willis Harman, he established the International Foundation for Advanced Study in Menlo Park to investigate LSD’s possible effects on personality and creativity. The foundation obtained an FDA research permit and began with supplies of LSD and mescaline from Hubbard. Here the chain from distribution to institutional research is explicit: a supply passed through Hubbard to an organization that had secured permission to study the drugs, allowing an experimental program to take shape outside the conventional treatment of illness alone.

Hubbard’s 1955 Commission for the Study of Creative Imagination had already signaled a broader ambition. He recruited researchers including Osmond, Hoffer, Huxley, and Cohen, along with philosopher Gerald Heard and a United Nations official, and named himself scientific director. The commission’s practical reach is uncertain, but its existence marked an effort to organize the research network around questions extending beyond medicine. As Hubbard’s own stated regard for science as an end in itself diminished, the aims associated with psychedelic work increasingly included cultural change and the development of creative potential.

Circulation, legacy, and limits

The drug’s movement through Hubbard’s network helps explain why Delysid’s distribution mattered beyond any single session or institution. Hubbard connected clinical researchers, therapists, and emerging research groups, while his supply of LSD supported work in settings as different as hospital treatment and the study of creativity. The book describes him as a carrier of information, chemicals, and clinical expertise; the metaphor captures a network whose links depended substantially on personal contact and practical assistance.

That network also carried a tension between medical and spiritual understandings of psychedelic experience. The high-dose psychedelic approach associated with Osmond, Hubbard, and Aldous Huxley challenged established psychiatric expectations: rather than treating LSD simply as a model of psychosis or an adjunct to psychoanalysis, it used a powerful session in pursuit of a transformative experience. Hubbard’s attention to words, objects, music, and the session environment treated suggestibility as something that could be used in healing. The drug’s effects were thus understood in relation to the setting and the guide, not merely as the isolated action of a chemical.

This history also clarifies why later scientific evaluation proved difficult. Researchers could not readily separate LSD’s pharmacological effects from participants’ expectations, the presence of guides, and the surrounding conditions of a session; participants and guides could often tell whether the drug or a placebo had been given. The circulation that enabled therapeutic experimentation therefore helped expose a methodological problem: the experience being studied was bound up with the circumstances in which the substance was used.

The book presents Delysid’s distribution as an initiating condition, not a guarantee of consensus or lasting institutional acceptance. LSD passed from Sandoz into a network that generated clinical practice, research, and arguments over the boundaries between science and spirituality. The drug’s route through Hubbard and the groups he served reveals the central consequence of making it available: research depended on relationships, methods, and settings as much as on the molecule itself.